Novartis AG (NVSEF) stock
NVSEFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVS
$146.46+2.56 (+1.78%)
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Novartis free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2025 it was $17.60B, up 8.3% from the year before. Over ten years it grew 6.3% a year on average. The highest annual figure on record is $17.60B in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.60B | +8.3% |
| FY2024 | Dec 31, 2024 | $16.25B | +21.3% |
| FY2023 | Dec 31, 2023 | $13.40B | +0.6% |
| FY2022 | Dec 31, 2022 | $13.32B | -4.9% |
| FY2021 | Dec 31, 2021 | $14.01B | +13.2% |
| FY2020 | Dec 31, 2020 | $12.38B | +1.1% |
| FY2019 | Dec 31, 2019 | $12.25B | -5.9% |
| FY2018 | Dec 31, 2018 | $13.02B | +15.2% |
| FY2017 | Dec 31, 2017 | $11.30B | +17.5% |
| FY2016 | Dec 31, 2016 | $9.61B | +0.9% |
| FY2015 | Dec 31, 2015 | $9.53B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.56B | +59.0% |
| Q2 FY2025 | Jun 30, 2025 | $6.33B | +66.2% |
| Q2 FY2024 | Jun 30, 2024 | $4.62B | +24.0% |
| Q2 FY2023 | Jun 30, 2023 | $3.35B | +18.3% |
| Q2 FY2022 | Jun 30, 2022 | $3.50B | -5.1% |
| Q2 FY2021 | Jun 30, 2021 | $3.81B | – |
| Q2 FY2020 | Jun 30, 2020 | $3.72B | – |
| Q2 FY2019 | Jun 30, 2019 | $2.83B | – |
| Q2 FY2018 | Jun 30, 2018 | $3.69B | – |
See a number that looks wrong?